Trials / Terminated
TerminatedNCT04607148
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 144 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of intravitreal (ITV) injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who completed the parent study (NCT03972709/GR40973).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galegenimab | Intravitreal (ITV) injections of galegenimab |
Timeline
- Start date
- 2020-11-16
- Primary completion
- 2022-11-14
- Completion
- 2022-11-14
- First posted
- 2020-10-29
- Last updated
- 2023-10-16
- Results posted
- 2023-10-16
Locations
48 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04607148. Inclusion in this directory is not an endorsement.